Parkman Healthcare Partners LLC Sells 730,844 Shares of Applied Therapeutics, Inc. (NASDAQ:APLT)

Parkman Healthcare Partners LLC lowered its stake in Applied Therapeutics, Inc. (NASDAQ:APLTFree Report) by 41.8% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 1,019,156 shares of the company’s stock after selling 730,844 shares during the quarter. Parkman Healthcare Partners LLC’s holdings in Applied Therapeutics were worth $3,414,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the stock. AIGH Capital Management LLC acquired a new position in Applied Therapeutics in the 3rd quarter valued at $1,975,000. EAM Investors LLC bought a new position in Applied Therapeutics in the 3rd quarter worth approximately $975,000. Schonfeld Strategic Advisors LLC acquired a new position in shares of Applied Therapeutics during the third quarter worth approximately $1,139,000. Armistice Capital LLC bought a new stake in shares of Applied Therapeutics in the third quarter valued at approximately $8,466,000. Finally, Rock Springs Capital Management LP grew its stake in shares of Applied Therapeutics by 3.6% in the third quarter. Rock Springs Capital Management LP now owns 808,809 shares of the company’s stock worth $2,014,000 after acquiring an additional 28,018 shares during the last quarter. 98.31% of the stock is owned by institutional investors.

Applied Therapeutics Stock Performance

Shares of NASDAQ:APLT traded down $0.01 during midday trading on Thursday, reaching $5.26. 1,117,385 shares of the company’s stock were exchanged, compared to its average volume of 1,557,628. The company’s 50 day simple moving average is $4.62 and its two-hundred day simple moving average is $4.28. Applied Therapeutics, Inc. has a 12 month low of $1.18 and a 12 month high of $9.39. The firm has a market capitalization of $601.04 million, a PE ratio of -2.86 and a beta of 1.88.

Applied Therapeutics (NASDAQ:APLTGet Free Report) last announced its quarterly earnings results on Thursday, May 9th. The company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.09). The business had revenue of $0.19 million for the quarter, compared to analysts’ expectations of $10.00 million. On average, research analysts anticipate that Applied Therapeutics, Inc. will post -0.59 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts recently commented on APLT shares. Royal Bank of Canada reiterated an “outperform” rating and set a $12.00 target price on shares of Applied Therapeutics in a research note on Thursday, April 11th. SVB Leerink started coverage on shares of Applied Therapeutics in a research note on Thursday, February 22nd. They issued an “outperform” rating and a $12.00 target price for the company. UBS Group lifted their target price on Applied Therapeutics from $12.00 to $13.00 and gave the stock a “buy” rating in a research report on Friday, March 15th. Citigroup upped their price target on Applied Therapeutics from $5.00 to $7.00 and gave the company a “buy” rating in a report on Friday, February 16th. Finally, Leerink Partnrs reissued an “outperform” rating on shares of Applied Therapeutics in a report on Thursday, February 22nd. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $11.00.

Check Out Our Latest Research Report on APLT

Insider Buying and Selling

In other Applied Therapeutics news, CEO Shoshana Shendelman sold 61,795 shares of the company’s stock in a transaction on Thursday, June 6th. The stock was sold at an average price of $4.32, for a total value of $266,954.40. Following the sale, the chief executive officer now directly owns 3,756,019 shares in the company, valued at $16,226,002.08. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, major shareholder Real Estate Equitie Alexandria sold 150,000 shares of the business’s stock in a transaction that occurred on Tuesday, June 4th. The stock was sold at an average price of $4.21, for a total value of $631,500.00. Following the transaction, the insider now directly owns 6,005,077 shares of the company’s stock, valued at approximately $25,281,374.17. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Shoshana Shendelman sold 61,795 shares of the stock in a transaction that occurred on Thursday, June 6th. The stock was sold at an average price of $4.32, for a total value of $266,954.40. Following the sale, the chief executive officer now owns 3,756,019 shares in the company, valued at $16,226,002.08. The disclosure for this sale can be found here. Insiders sold 250,778 shares of company stock worth $1,066,861 in the last 90 days. 8.60% of the stock is owned by company insiders.

About Applied Therapeutics

(Free Report)

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.

Featured Stories

Want to see what other hedge funds are holding APLT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Applied Therapeutics, Inc. (NASDAQ:APLTFree Report).

Institutional Ownership by Quarter for Applied Therapeutics (NASDAQ:APLT)

Receive News & Ratings for Applied Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.